-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UQ8a8L+v6tyDjnuh9bynTPEyPAZ+YY2eGKvZa3Z/FeY4Kjzak5FsFtTFQ4KpJTBA 16J5oIw98iJi7XHTERb9Lg== 0000897069-09-001299.txt : 20090812 0000897069-09-001299.hdr.sgml : 20090812 20090812165056 ACCESSION NUMBER: 0000897069-09-001299 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090810 FILED AS OF DATE: 20090812 DATE AS OF CHANGE: 20090812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARTIN JEFFREY L CENTRAL INDEX KEY: 0001456531 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10670 FILM NUMBER: 091007447 MAIL ADDRESS: STREET 1: HANGER ORTHOPEDIC GROUP, INC. STREET 2: TWO BETHESDA METRO CENTER, SUITE 1200 CITY: BETHESDA STATE: MD ZIP: 20814 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HANGER ORTHOPEDIC GROUP INC CENTRAL INDEX KEY: 0000722723 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 840904275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TWO BETHESDA METRO CENTER STREET 2: SUITE 1300 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 3019860701 MAIL ADDRESS: STREET 1: TWO BETHESDA METRO CENTER STREET 2: SUITE 1300 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: SEQUEL CORP DATE OF NAME CHANGE: 19890814 FORMER COMPANY: FORMER CONFORMED NAME: CELLTECH COMMUNICATIONS INC DATE OF NAME CHANGE: 19860304 4 1 cmw4445_ex.xml X0303 4 2009-08-10 0 0000722723 HANGER ORTHOPEDIC GROUP INC HGR 0001456531 MARTIN JEFFREY L TWO BETHESDA METRO CENTER, SUITE 1200 BETHESDA MD 20814 0 1 0 0 Pres. Innovative Neurotronics Common Stock 2009-08-10 4 S 0 970 14.1006 D 28340 D Incentive Stock Option 16.75 2003-09-17 2012-09-16 Common Stock 4000 4000 D The shares of common stock were sold to cover taxes incurred as a result of the vesting of restricted shares. These shares were sold at a range of sale prices from $14.10 to $14.1008. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Includes vested and unvested restricted shares from previous awards of restricted stock to the reporting person. All remaining unvested restricted shares will continue to vest at a rate of 25% per year of the original grant amount on the anniversary date of the grant. This option vested over a four-year period from the date of grant and is now fully vested. /s/ Teri L. Champ, Attorney-in-Fact 2009-08-12 -----END PRIVACY-ENHANCED MESSAGE-----